Be Careful of those Flying Champagne Corks

As this season’s football teams celebrated their respective division championships with champagne, with corks flying around the room painting each others’ faces with the pressurized spray, I was motivated to warn my readers about avoiding a potentially devastating eye injury. Just three months ago, I received a phone call from one of my office employees. […]

The Avastin versus Lucentis Controversy Continues

Lucentis, a chemical cousin to Avastin, are both made by the Genentech. Although only Lucentis has been approved by the FDA for use against wet macular degeneration, Avastin may be just as effective and at only 2% of the cost. This has resulted in a political controversy dictated not only by Genentech trying to recover from its valid discovery of a useful treatment for AMD, but also by the heavy cost burden incurred by the United States government’s Medicare plan, private health care insurance companies, and farthest down the ladder, physicians themselves.

Happy New Year! Our New Blog Has Arrived!

Welcome to the VisiVite Blog, featuring subjects about eye health and alternative treatments for macular degeneration and dry eye syndrome, in particular.

Off-Label Drug Offers Similar Results at Lower Price

It seems highly unlikely that one company would produce two drugs, at different prices, that treat the same ailment, and be in the middle of a medical industry dispute, but that’s exactly the case of Genentech Inc.